Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?

Core Viewpoint - Exagen Inc. has experienced significant stock performance, with a 42.6% increase over the past month and a 38.7% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Products industry [1] Financial Performance - Exagen has consistently exceeded earnings expectations, reporting an EPS of -$0.16 against a consensus estimate of -$0.36 in its last earnings report [2] - For the current fiscal year, Exagen is projected to have an EPS of -$1.03 on revenues of $57.05 million, reflecting a 23.13% change in EPS and an 8.57% change in revenues [3] - The next fiscal year forecasts an EPS of -$0.74 on revenues of $64.85 million, indicating a year-over-year change of 27.67% in EPS and 13.67% in revenues [3] Valuation Metrics - Exagen's current valuation metrics suggest it may be at a 52-week high, prompting a review of its future stock performance [4] - The Zacks Style Scores indicate Exagen has a Value Score of C, a Growth Score of B, and a Momentum Score of A, resulting in a combined VGM Score of B [6] Zacks Rank - Exagen holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts, suggesting potential for further gains [7]